|
1
|
Friedman SL: Molecular regulation of
hepatic fibrosis, an integrated cellular response to tissue injury.
J Biol Chem. 275:2247–2250. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng M and Yang C: The Basic Study and
Clinical Research on Hepatic Fibrosis. First edition. First Jumbo
Publishing Co; California, USA: 2002
|
|
3
|
Moreira RK: Hepatic stellate cells and
liver fibrosis. Arch Pathol Lab Med. 131:1728–1734. 2007.PubMed/NCBI
|
|
4
|
Wu J and Zern MA: Hepatic stellate cells:
a target for the treatment of liver fibrosis. J Gastroenterol.
35:665–672. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mann J and Mann DA: Transcriptional
regulation of hepatic stellate cells. Adv Drug Deliv Rev.
61:497–512. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gäbele E, Brenner DA and Rippe RA: Liver
fibrosis: signals leading to the amplification of the fibrogenic
hepatic stellate cell. Front Biosci. 8:d69–d77. 2003.PubMed/NCBI
|
|
7
|
Zou YH, Yang Y, Li J, et al: Potential
therapeutic effects of a traditional Chinese formulation, BJ-JN, on
liver fibrosis induced by carbon tetrachloride in rats. J
Ethnopharmacol. 120:452–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Purps O, Lahme B, Gressner AM,
Meindl-Beinker NM and Dooley S: Loss of TGF-beta dependent growth
control during HSC transdifferentiation. Biochem Biophys Res
Commun. 353:841–847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Borkham-Kamphorst E, van Roeyen CR,
Ostendorf T, Floege J, Gressner AM and Weiskirchen R:
Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol.
46:1064–1074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brewster UC, Setaro JF and Perazella MA:
The renin-angiotensin-aldosterone system: cardiorenal effects and
implications for renal and cardiovascular disease states. Am J Med
Sci. 326:15–24. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cadigan KM and Nusse R: Wnt signaling: a
common theme in animal development. Genes Dev. 11:3286–3305. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin X, Zhang S, Huang Q, et al: Protective
effect of Fufang-Liu-Yue-Qing, a traditional Chinese herbal
formula, on CCl4 induced liver fibrosis in rats. J Ethnopharmacol.
142:548–556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu TT, Jiang MN, Li C, Che Y and Jia YJ:
Effect of Chinese traditional compound, Gan-fu-kang, on
CCl(4)-induced liver fibrosis in rats and its probable molecular
mechanisms. Hepatol Res. 37:221–229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao Y, Song LX, Jiang MN, Ge GY and Jia
YJ: Effects of traditional chinese medicine on endotoxin and its
receptors in rats with non-alcoholic steatohepatitis. Inflammation.
31:121–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee PN, Pang K, Matus DQ and Martindale
MQ: A WNT of things to come: evolution of Wnt signaling and
polarity in cnidarians. Semin Cell Dev Biol. 17:157–167. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao J, Kim KA and Abo A: Tipping the
balance: modulating the Wnt pathway for tissue repair. Trends
Biotechnol. 27:131–136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lustig B and Behrens J: The Wnt signaling
pathway and its role in tumor development. J Cancer Res Clin Oncol.
129:199–221. 2003.PubMed/NCBI
|
|
18
|
Kikuchi A and Yamamoto H: Tumor formation
due to abnormalities in the β-catenin-independent pathway of Wnt
signaling. Cancer Sci. 99:202–208. 2008.
|
|
19
|
Zhang B, Zhou KK and Ma JX: Inhibition of
connective tissue growth factor overexpression in diabetic
retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway.
Diabetes. 59:1809–1816. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morrisey EE: Wnt signaling and pulmonary
fibrosis. Am J Pathol. 162:1393–1397. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Habas R and Dawid IB: Dishevelled and Wnt
signaling: is the nucleus the final frontier? J Biol. 4:22005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ross SE, Hemati N, Longo KA, Bennett CN,
Lucas PC, Erickson RL and MacDougald OA: Inhibition of adipogenesis
by Wnt signaling. Science. 289:950–953. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng JH, She H, Han YP, et al: Wnt
antagonism inhibits hepatic stellate cell activation and liver
fibrosis. Am J Physiol Gastrointest Liver Physiol. 294:G39–G49.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lou JL, Jiang MN, Li C, et al: Herb
medicine Gan-fu-kang attenuates liver injury in a rat fibrotic
model. J Ethnopharmacol. 128:131–138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
National Institutes of Health. Guide for
the Care and Use of Laboratory Animals. Sixth edition. National
Acadamies Press; Washington, D.C: 1985
|
|
27
|
Nie QH, Cheng YQ, Xie YM, Zhou YX and Cao
YZ: Inhibiting effect of antisense oligonucleotides phosphorthioate
on gene expression of TIMP-1 in rat liver fibrosis. World J
Gastroenterol. 7:363–369. 2001.PubMed/NCBI
|
|
28
|
Dignani JD, Lebovitz RM and Roeder RG:
Accurate transcription initiation by RNA polymerase II in a soluble
extract from isolated mammalian nuclei. Nucleic Acids Res.
11:1475–1489. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Castera L: Assessing liver fibrosis.
Expert Rev Gastroenterol Hepatol. 2:541–552. 2008. View Article : Google Scholar
|
|
30
|
Faria SC, Ganesan K, Mwangi I, et al: MR
imaging of liver fibrosis: current state of the art. Radiographics.
29:1615–1635. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Watson MR, Wallace K, Gieling RG, et al:
NF-kappaB is a critical regulator of the survival of rodent and
human hepatic myofibroblasts. J Hepatol. 48:589–597. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsukada S, Parsons CJ and Rippe RA:
Mechanisms of liver fibrosis. Clin Chim Acta. 364:33–60. 2006.
View Article : Google Scholar
|
|
33
|
Friedman SL: Liver fibrosis-from bench to
bedside. J Hepatol. 38:S38–S53. 2003. View Article : Google Scholar
|
|
34
|
Fowell AJ and Iredale JP: Emerging
therapies for liver fibrosis. Dig Dis. 24:174–183. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sturgill MG and Lambert GH:
Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and
methods of monitoring hepatic function. Clin Chem. 43:1512–1526.
1997.PubMed/NCBI
|
|
36
|
Achliya GS, Wadodkar SG and Dorle AK:
Evaluation of hepatoprotective effect of Amalkadi Ghrita against
carbon tetrachloride-induced hepatic damage in rats. J
Ethnopharmacol. 90:229–232. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leroy V: Other non-invasive markers of
liver fibrosis. Gastroenterol Clin Biol. 32(6 Suppl 1): 52–57.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bataller R and Brenner DA: Liver fibrosis.
J Clin Invest. 115:209–218. 2005. View Article : Google Scholar
|
|
39
|
Lotersztajn S, Julien B, Teixeira-Clerc F,
Grenard P and Mallat A: Hepatic fibrosis: molecular mechanisms and
drug targets. Annu Rev Pharmacol Toxicol. 45:605–628. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li D and Friedman SL: Liver fibrogenesis
and the role of hepatic stellate cells: new insights and prospects
for therapy. J Gastroenterol Hepatol. 14:618–633. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han YP: Matrix metalloproteinases, the
pros and cons, in liver fibrosis. J Gastroenterol Hepatol. 21(Suppl
3): S88–S91. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lichtinghagen R, Michels D, Haberkorn CI,
et al: Matrix metalloproteinase (MMP)-2, MMP-7 and tissue inhibitor
of metalloproteinase-1 are closely related to the
fibroproliferative process in the liver during chronic hepatitis C.
J Hepatol. 34:239–247. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Arthur MJ, Mann DA and Iredale JP: Tissue
inhibitors of metalloproteinases, hepatic stellate cells and liver
fibrosis. J Gastroenterol Hepatol. 13:S33–S38. 1998.PubMed/NCBI
|
|
44
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chilosi M, Poletti V, Zamò A, et al:
Aberrant Wnt/beta-catenin pathway activation in idiopathic
pulmonary fibrosis. Am J Pathol. 162:1495–1502. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Königshoff M, Balsara N, Pfaff EM, et al:
Functional Wnt signaling is increased in idiopathic pulmonary
fibrosis. PLoS One. 3:e21422008.PubMed/NCBI
|
|
47
|
Luk JM, Wang X, Liu P, et al: Traditional
Chinese herbal medicines for treatment of liver fibrosis and
cancer: from laboratory discovery to clinical evaluation. Liver
Int. 27:879–890. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
He W, Dai C, Li Y, Zeng G, Monga SP and
Liu Y: Wnt/beta-catenin signaling promotes renal interstitial
fibrosis. J Am Soc Nephrol. 20:765–776. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brack AS, Conboy MJ, Roy S, et al:
Increased Wnt signaling during aging alters muscle stem cell fate
and increases fibrosis. Science. 317:807–810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jiang F, Parsons CJ and Stefanovic B: Gene
expression profile of quiescent and activated rat hepatic stellate
cells implicates Wnt signaling pathway in activation. J Hepatol.
45:401–409. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Myung SJ, Yoon JH, Gwak GY, et al: Wnt
signaling enhances the activation and survival of human hepatic
stellate cells. FEBS Lett. 581:2954–2958. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kordes C, Sawitza I and Häussinger D:
Canonical Wnt signaling maintains the quiescent stage of hepatic
stellate cells. Biochem Biophys Res Commun. 367:116–123. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: components, mechanisms and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ying J, Li H, Yu J, et al: WNT5A exhibits
tumor-suppressive activity through antagonizing the
Wnt/beta-catenin signaling, and is frequently methylated in
colorectal cancer. Clin Cancer Res. 14:55–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Albrecht JH and Hansen LK: Cyclin D1
promotes mitogen-independent cell cycle progression in hepatocytes.
Cell Growth Differ. 10:397–404. 1999.PubMed/NCBI
|
|
56
|
Houseknecht KL, Cole BM and Steele PJ:
Peroxisome proliferator-activated receptor gamma (PPARgamma) and
its ligands: a review. Domest Anim Endocrinol. 22:1–23. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Galli A, Crabb DW, Ceni E, et al:
Antidiabetic thiazolidinediones inhibit collagen synthesis and
hepatic stellate cell activation in vivo and in vitro.
Gastroenterology. 122:1924–1940. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liu J and Farmer SR: Regulating the
balance between peroxisome proliferator-activated receptor gamma
and beta-catenin signaling during adipogenesis. A glycogen synthase
kinase 3beta phosphorylation-defective mutant of beta-catenin
inhibits expression of a subset of adipogenic genes. J Biol Chem.
279:45020–45027. 2004.
|
|
59
|
Moldes M, Zuo Y, Morrison RF, et al:
Peroxisome-proliferator-activated receptor gamma suppresses
Wnt/betacatenin signalling during adipogenesis. Biochem J.
376:607–613. 2003. View Article : Google Scholar : PubMed/NCBI
|
